NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)'s Matt Liddelow sits down with Proactive to paint a picture of the company's current operations and future plans. The healthcare stock is developing novel, peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have a high unmet medical need. Ultimately, NSB's vision is to transform how the pharmaceutical industry approaches the understanding and treatment of neurodegenerative diseases such as Alzheimer’s disease.
NeuroScientific Biopharmaceuticals targets neurodegenerative disorders with novel peptide solution
